Company intelligence / Profile preview

Evercyte

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Evercyte provides validated human cell models for in vitro testing, drug screening, and production of extracellular vesicles; its platforms are used for preclinical research and are being explored for potential clinical applications, especially in tissue regeneration and drug delivery. No clinical trial results reported.

Therapeutic areas: OtherImmunology
Modalities: Cell therapyExtracellular vesicle-based therapyRecombinant proteinGene editingReprogramming
Industry: Non-Drug Biotech

Partnerships

MDimune (collaboration for tumor-targeted extracellular vesicles)

Beyond the preview

Go deeper on Evercyte.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evercyte.

Explore the full profile